Mitchell Blutt

An innovator in the field of health care investment, Mitchell Blutt complements his professional responsibilities by having sat on the board of Penn Medicine, a part of the University of Pennsylvania Health System. As a board member, Mitchell Blutt developed intimate familiarity with the research centers on Penn Medicine’s campus. Below are descriptions of three such centers. Abramson Cancer Center The Abramson Cancer Center focuses on clinical trials that address detection, diagnosis, and prevention of various cancer types, including breast and prostate cancers, among others. Institute for Translational Medicine and Therapeutics The Institute for Translational Medicine and Therapeutics, or ITMAT, is dedicated to pursuing research at the forefront of modern medicine. ITMAT supports research for all of the medical research centers on Penn Medicine’s campus. Penn Cardiovascular Institute The Penn Cardiovascular Institute serves patients with cardiovascular issues, which are a leading cause of death in the United States. The institute not only conducts clinical trials but also performs innovative treatments on patients. Learn more about the research centers at Penn Medicine by visiting www.pennmedicine.org.

As the former Executive Partner at J. P. Morgan Partners, Mitchell Blutt currently works as the CEO of the healthcare investment firm Consonance Capital. Considered a pioneer in the medical field, Mitchell Blutt also serves as part of the Dean's Council of Weill Cornell Medical College. Founded in 1898 and affiliated with New York-Presbyterian Hospital, the college is one of the top medical and clinical research facilities in the country. With 24 separate patient care and science departments, the medical college focuses on clinical medicine as well as prevention and treatment of different types of diseases. Throughout the year, the medical college offers webinars and other meetings to provide members with additional training and experience. One such event pertains to pain management coding and is scheduled to take place on Wednesday, September 24, 2014. Attendees will study the different types of codes involving electromyography (EMG) and nerve conductor velocity (NCV). The American Academy of Professional Coders assists with the webinar, along with the medical center's billing and coding department.

A physician and professor at Weill Cornell Medical College, Dr. Mitchell Blutt also serves as chief executive officer and founder of Consonance Capital. Dr. Mitchell Blutt first entered the health care investment industry at JPMorgan Partners, where he established and managed a new health care division and eventually became the Executive Partner of the firm. Headquartered in New York City, Consonance Capital operates a private equity fund specializing in US health care industry investments. Led by four cofounders with a combined total of nearly 70 years of private equity experience. The firm also operates Consonance Capital Management, a healthcare public equity hedge fund. The company’s investment strategy focuses on identifying strong management teams with track records of dealing with the complexities of the health care industry. Consonance Capital Partners targets firms in the lower-middle market whose products or services improve care and lower costs. These include private companies seeking liquidity and/or capital to pursue growth opportunities as well as large companies selling off peripheral assets. Consonance Capital Management targets publicly traded healthcare companies in therapeutics, medical products, healthcare services and healthcare information technology that are in transformational circumstances.